Sandoz to license three biosimilar drugs from Shanghai Henlius Biotech

Reports

3

Domains carrying it

3

First reported

17 August 2026

Latest report

17 August 2026

◆ Sectors

◆ Where

China

◆ Timeline

1. 17 August 2026Sandoz to license three biosimilar drugs from Shanghai Henlius Biotechreuters.com
2. 17 August 2026Henlius, Sandoz Broaden Biosimilar Tie-Up Deal For Up To 10 Productsrttnews.com

◆ Connected developments

Situations Wire finds semantically close to this one. Proximity, not cause.

• Dr Reddy's wins FDA nod for rituximab biosimilar5 reports · 5 domains · 14 August 2026
• How Investors Are Reacting To Replimune Group (REPL) FDA Accelerated Approval For ...4 reports · 4 domains · 10 August 2026
• Trinity Biotech Secures $7M, Regains Nasdaq Compliance2 reports · 2 domains · 17 August 2026
• Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis4 reports · 4 domains · 4 September 2026
• FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients2 reports · 2 domains · 28 August 2026

◆ Share

◆ Evidence

3 reports · 3 domains

• Henlius, Sandoz Broaden Biosimilar Tie-Up Deal For Up To 10 Productsrttnews.com · 17 August 2026
• Sandoz to license three biosimilar drugs from Shanghai Henlius Biotechsrnnews.com · 17 August 2026
• Sandoz to license three biosimilar drugs from Shanghai Henlius Biotechreuters.com · 17 August 2026